Deep Track Biotechnology Master Fund, Ltd. bought LBRX
September 12, 2025 · Form 4 insider transaction
Deep Track Biotechnology Master Fund, Ltd. bought 2,000,000 shares of LB Pharmaceuticals Inc at $15.00 per share, a transaction worth $30.00M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.